PDSB), a clinical-stage immuno-oncology company pioneering the development of novel multifunctional immunotherapeutic products, today announced its financial results for the first quarter ended March 31, 2019.
For the first quarter of 2019, net income was approximately $6.8 million, or $1.82 per basic share and $1.47 per diluted share, compared to a net loss of approximately $(0.7) million, or $(0.24) per basic and diluted share for the first quarter of 2018.
Research and development expenses totaled approximately $1.0 million for the first quarter of 2019, compared to approximately $0.2 million for the same period in 2018, an increase of 412%. These expenses include employee-related expenses, licensing fees to use certain technology in PDS’ research and development projects, costs of acquiring, developing and manufacturing clinical trial materials, as well as fees paid to consultants and various entities that perform certain research and testing on PDS’ behalf.
For the first quarter of 2019, general and administrative expenses were approximately $3.9 million compared with approximately $0.5 million for the first quarter of 2018, an increase of 629%. The increase is primarily attributable to an increase in non-cash stock compensation expense of $2.3 million and bonuses of $0.4 million. In addition, there was an increase in D&O insurance of $0.1 million, professional consulting fees of $0.1 million, as well as legal fees of $0.4 million.
Total operating expenses for the first quarter of 2019 were approximately $4.9 million, compared to total operating expenses of approximately $0.7 million for the same period in 2018, an increase of 570%.
The Company recognized a gain on bargain purchase of approximately $11.7 million in connection with the merger with Edge. The gain represents the difference between the book value of Edge assets compared to the cash value of stock granted to legacy Edge shareholders.
As of March 31, 2019, the Company’s cash balance was approximately $26.6 million.
www.pdsbiotech.com.” data-reactid=”26″>For additional information about PDS, please visit www.pdsbiotech.com.
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability of the Company to integrate Edge and PDS Biotechnology following the merger; the Company’s ability to protect its intellectual property rights; competitive responses to the completion of the merger; potential adverse reactions or changes to business relationships resulting from the completion of the merger; the Company’s ability to access capital markets, the timing for the Company to initiate two clinical trials for its lead asset, PDS0101; the successful implementation of the Company’s research and development programs and collaborations; the acceptance by the market of the Company’s product candidates, if approved; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
email@example.com / firstname.lastname@example.org” data-reactid=”33″>Media & Investor Relations Contact:
Tram Bui / Alexander Lobo
The Ruth Group
Phone: +1-646-536-7035 / +1-646-536-7037
Email: email@example.com / firstname.lastname@example.org
(Financial Statements to Follow)
|March 31, 2019||December 31, 2018|
|Cash and cash equivalents||$||26,592,845||$||103,695|
|Prepaid expenses and other current assets||1,313,931||156,628|
|Total current assets||27,906,776||260,323|
|Property and equipment, net||412,735||29,508|
|Intangible assets, net||1,223,000||41,692|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Operating lease liability- short term||477,300||–|
|Total current liabilities||5,538,124||2,014,840|
|Deferred tax liability||157,000||–|
|Operating lease liability- long term||902,972||–|
|Convertible promissory notes payable||–||30,000|
|Preferred stock, 5,000,000 shares authorized at March 31, 2019 and December 31, 2018, 0 outstanding||–||–|
|Common stock, $0.00033 par value, 75,000,000 shares authorized at March 31, 2019 and December 31, 2018, 5,172,938 shares and 3,417,187 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively||1,707||1,128|
|Additional paid-in capital||38,642,411||19,311,529|
|Total stockholders’ equity||24,447,642||(1,700,517||)|
|Total liabilities and stockholders’ equity||$||31,045,738||$||344,323|
|PDS BIOTECHNOLOGY CORPORATION|
|Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)|
|Three Months Ended March 31,|
|Research and development expenses||$||1,030,003||$||201,138|
|General and administrative expenses||3,905,877||535,801|
|Total operating expenses||4,935,880||736,939|
|Loss from operations||(4,935,880||)||(736,939||)|
|Other income (expense):|
|Gain on bargain purchase||11,729,882||–|
|Comprehensive income (loss)||$||6,816,698||$||(737,892||)|
|Per share information:|
|Net income (loss) per share, basic||$||1.82||$||(0.24||)|
|Net income (loss) per share, diluted||$||1.47||$||(0.24||)|
|Weighted average common shares outstanding, basic||3,748,325||3,099,311|
|Weighted average common shares outstanding, diluted||4,625,295||3,099,311|